Article

Ruboxistaurin slows central DME, does not halt progression

Inhibition of PKC shown to affect changes in retinal blood flow as well as leukocyte adhesion

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Inflammasome Therapeutics reports positive results from early K8 GA trial
September 17th 2025

Inflammasome Therapeutics reports positive results from early K8 GA trial

3 Things You Should Know About the GA Pipeline
September 17th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

STAAR Surgical files definitive proxy statement on pending merger with Alcon
September 17th 2025

STAAR Surgical files definitive proxy statement on pending merger with Alcon

3 Things You Should Know About the GA Pipeline
September 17th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Sagent Pharmaceuticals enters ophthalmic market, launches travoprost ophthalmic solution, USP 0.004%
September 17th 2025

Sagent Pharmaceuticals enters ophthalmic market, launches travoprost ophthalmic solution, USP 0.004%

Q&A: Sofia Androudi on retinal disorders mimicking inherited retinal diseases
September 17th 2025

Q&A: Sofia Androudi on retinal disorders mimicking inherited retinal diseases

© 2025 MJH Life Sciences

All rights reserved.